Engle Martin Announces the Acquisition of Integra, Advancing Specialty Claims Expertise Globally
7.10.2025 13:00:00 CEST | Business Wire | Press Release
Engle Martin & Associates, LLC (“Engle Martin”), a market-leading independent loss adjusting and claims management provider, announced today its acquisition of Integra Technical Services Group (“Integra”), a specialty international loss adjusting firm headquartered in London, England.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007106413/en/
Founded in 1998, Integra has built a strong reputation for managing high-value and complex claims across a range of specialty industries, including construction and engineering, energy, manufacturing, advanced technologies, mining, marine, specialist liabilities, and risk engineering. With over 50 experienced claims professionals and offices strategically located throughout the United States, Europe, Asia, Australia, New Zealand, the Middle East, and Latin America, Integra delivers expert-led adjusting solutions that align with the unique challenges of global markets.
“This is an exciting and meaningful milestone for Engle Martin,” said Stephen Beene, President of Engle Martin. “The addition of Integra not only accelerates our global strategy but also brings a talented team with deep technical knowledge and a respected market presence. We share a culture that values people and performance as well as a commitment to delivering innovative, high-quality service to clients. We’re proud to welcome Integra to the Engle Martin family.”
Integra will continue operating as a standalone business, retaining its established brand, leadership team, and service model. The current leadership will maintain full operational oversight of the company’s portfolio, ensuring continuity for clients and team members.
“This acquisition marks a strategic step in Engle Martin’s continued growth and international expansion,” commented Jay Campbell, Executive Vice President – Strategy & Organizational Growth at Engle Martin. “It enhances our capabilities in large loss adjusting and specialty sectors, strengthens our operations in the United States, and significantly broadens our global reach. By combining our complementary strengths, we are better positioned to meet the evolving needs of clients worldwide.”
Ewan Cresswell, Chairman and Founder of Integra, added, “Joining Engle Martin marks a new and significant chapter for Integra. This partnership aligns with our values, provides greater operational support, and strengthens our presence in the United States, while enabling us to continue serving clients across both established and emerging markets. This alignment enhances our global platform while preserving the specialized services and high technical expertise that define Integra.”
This acquisition strengthens Engle Martin’s position as a trusted global partner in loss adjusting and claims management, while underscoring its continued investment in talent, innovation, and international service expansion.
About Engle Martin:
Engle Martin & Associates, LLC is a market-leading independent loss adjusting and claims management provider. Engle Martin offers a comprehensive suite of services, including commercial property, casualty, inland and ocean marine, appraisal/umpire, and specialty audits. With over 800 claims professionals across 75 U.S. locations, Engle Martin is committed to delivering results-driven and client-focused solutions. Learn more at www.englemartin.com
About Integra:
Integra Technical Services Group is a specialty international adjusting business established in 1998, with a reputation for having the abilities and experience to manage technical and specialist claims, as well as risk engineering globally. Integra is committed to being the loss adjuster of choice in every industry sector it serves by delivering technically based, high-quality service, and excellence in every appointment. Learn more at www.integratechnical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007106413/en/
Contacts
Media Contacts:
Engle Martin
Dominique Enriquez
Marketing Director
denriquez@englemartin.com
Integra
Doug Horne
Global Head of Marketing
doug.horne@integratechnical.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom